Delving into the Latest Updates on Xiajiang Hemei Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Neoplasms

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

TNF-α(Tumor necrosis factor α)	1
EGFR x HER2	1

主要目的：研究Hemay022联合卡培他滨口服给药在HER2阳性晚期乳腺癌患者中的耐受性和安全性并确定推荐的Ⅱ期剂量。次要目的：（1）研究Hemay022联合卡培他滨在HER2阳性晚期乳腺癌患者中的药代动力学特征。（2）初步探索Hemay022联合卡培他滨治疗HER2阳性晚期乳腺癌患者的临床有效性。

[Translation]

Primary objective: To study the tolerability and safety of oral administration of Hemay022 combined with capecitabine in patients with HER2-positive advanced breast cancer and determine the recommended phase II dose. Secondary objectives: (1) To study the pharmacokinetic characteristics of Hemay022 combined with capecitabine in patients with HER2-positive advanced breast cancer. (2) To preliminarily explore the clinical efficacy of Hemay022 combined with capecitabine in the treatment of patients with HER2-positive advanced breast cancer.

Start Date10 Jul 2019

Sponsor / Collaborator

Xiajiang Hemei Pharmaceutical Co., Ltd.

[+1]

CTR20150326

/ Active, not recruitingPhase 1

小分子EGFR/HER2酪氨酸激酶不可逆抑制剂Hemay022治疗晚期HER2阳性乳腺癌剂量递增Ⅰ期临床研究

[Translation] Phase I clinical study of dose escalation of Hemay022, a small molecule irreversible inhibitor of EGFR/HER2 tyrosine kinase, in the treatment of advanced HER2-positive breast cancer

主要目的：（1）评估Hemay022在晚期HER2阳性乳腺癌患者中单次给药和连续给药的安全性和耐受性。（2）确定Hemay022在晚期HER2阳性乳腺癌患者中单次给药和连续给药的药代动力学特征。（3）为后期临床试验推荐给药方案。次要目的：通过客观缓解指标初步评估Hemay022的抗肿瘤疗效。

[Translation]

Primary objectives: (1) To evaluate the safety and tolerability of single and continuous administration of Hemay022 in patients with advanced HER2-positive breast cancer. (2) To determine the pharmacokinetic characteristics of single and continuous administration of Hemay022 in patients with advanced HER2-positive breast cancer. (3) To recommend dosing regimens for later clinical trials. Secondary objectives: To preliminarily evaluate the anti-tumor efficacy of Hemay022 through objective response indicators.

Start Date30 Sep 2015

Sponsor / Collaborator

Xiajiang Hemei Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Xiajiang Hemei Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Xiajiang Hemei Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Xiajiang Hemei Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Xiajiang Hemei Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Phase 3

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Sacibertinib ( EGFR x HER2 )	Advanced breast cancer More	Phase 3
Hemay-102	Locally Advanced Hepatocellular Carcinoma More	Suspended
Hemay007 ( TNF-α )	Colitis, Ulcerative More	Discontinued